Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs GSK 2321138A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 22 Nov 2012 Results were presented at the IDweek in October 2012, according to a GlaxoSmithKline media release.
- 22 Nov 2012 Primary endpoint 'Haemagglutin-inhibition-antibody-levels' has been met.
- 17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.